NCT06833307

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to \<18 years with moderate-to-Severe plaque psoriasis

Conditions

• Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	SHR-1314	SHR-1314: dose 1 SHR-1314:dose 2 SHR-1314:dose 3

Timeline

• Start date: 2025-02-01
• Primary completion: 2026-07-01
• Completion: 2026-08-01
• First posted: 2025-02-18
• Last updated: 2025-02-18

Locations

2 sites across 1 country: China